FastForward Innovations Limited Investee Company Update: EMMAC Life Sciences (2504I)
March 31 2020 - 8:15AM
UK Regulatory
TIDMFFWD
RNS Number : 2504I
FastForward Innovations Limited
31 March 2020
FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End
Investments
31 March 2020
FastForward Innovations Ltd ("FastForward" or, "FFWD")
Investee Company Update: EMMAC Life Sciences Limited
FastForward Innovations Ltd, the AIM quoted company focusing on
making investments in fast growing and industry leading businesses,
notes the following announcement released on 31 March 2020
concerning investee company EMMAC Life Sciences Limited ("EMMAC").
FastForward has a current equity interest totalling 2.3% in the
stock of EMMAC.
Overview
-- EMMAC has secured pharmaceutical wholesaler and narcotics
handling permits for Germany, Europe's largest medical cannabis
market
-- Permits will enable EMMAC to drive immediate revenue growth
in Germany with the sale of medical cannabis products
-- EMMAC has a range of medical cannabis products, with
different strengths and THC/CBD/CBG formulations in Oil and Flos(1)
formats, to address a wide range of specialist requirements
The announcement is set out below without material changes or
adjustments.
31 March 2020, London. EMMAC Life Sciences Group, Europe's
leading independent cannabis company, is pleased to announce that
its wholly owned subsidiary, About Nature Health GmbH ("About
Nature"), has secured pharmaceutical wholesaler and narcotics
handling permits for Germany, Europe's largest medical cannabis
market. The permits, granted according to section 52a AMG (German
Pharmaceutical Law) and section 3 BMG (German Narcotics Law), will
enable EMMAC to drive immediate revenue growth in Germany with the
sale of medical cannabis products. EMMAC has a range of medical
cannabis products, with different strengths and THC/CBD/CBG
formulations in Oil and Flos(1) formats, to address a wide range of
specialist requirements.
According to the Bank of Montreal(2) , the German medical
cannabis market could potentially produce more than US$5 billion in
revenue for global cannabis producers, with an assumption that in
seven years 7.5% of sleep, anxiety and pain prescriptions in
Germany will be replaced with medical cannabis.
Antonio Costanzo, CEO of EMMAC, said: "The announcement today is
an important milestone for EMMAC, and demonstrates the EU GDP
compliant quality management systems About Nature has in place.
EMMAC is now poised to deliver immediate revenues from Germany and
capitalise on the significant opportunities presented by the
largest medical cannabis market in Europe, as we bring our products
to market in 2020."
(1) Dried female cannabis flower
(2)
https://business.financialpost.com/cannabis/cannabis-producers-could-be-chasing-global-market-worth-194-billion-in-seven-years-bmo-report
About EMMAC Life Sciences Group
EMMAC Life Sciences Group is Europe's leading independent
cannabis company, bringing together pioneering science and research
with cutting-edge cultivation, extraction and production. With a
unique supply and distribution network throughout Europe, EMMAC's
vision is to bring the life-enhancing potential of cannabis to the
people who need it.
Miscellaneous
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
CAUTIONARY STATEMENT
The AIM Market of London Stock Exchange plc does not accept
responsibility for the adequacy or accuracy of this release. No
stock exchange, securities commission or other regulatory authority
has approved or disapproved the information contained herein. All
statements, other than statements of historical fact, in this news
release are forward-looking statements that involve various risks
and uncertainties, including, without limitation, statements
regarding potential values, the future plans and objectives of
FastForward Innovations Ltd. There can be no assurance that such
statements will prove to be accurate, achievable or recognisable in
the near term.
Actual results and future events could differ materially from
those anticipated in such statements. These and all subsequent
written and oral forward-looking statements are based on the
estimates and opinions of management on the dates they are made and
are expressly qualified in their entirety by this notice. Fast
Forward Innovations assumes no obligation to update forward-looking
statements should circumstances or management's estimates or
opinions change.
ENDS
For further information on the Company please visit www.fstfwd.co or contact:
Ed McDermott / Lance FastForward Innovations Email: info@fstfwd.co
de Jersey Ltd
James Biddle / Roland Beaumont Cornish Tel: +44 (0) 207
Cornish Limited, 628 3396
Nomad
------------------------ ----------------------
Jeremy King Optiva Securities Tel: +44 (0) 203
Limited, 411 1881
Broker
------------------------ ----------------------
Isabel De Salis / Beth St Brides Partners Tel: +44 (0)207
Melluish Ltd, 236 1177
Financial PR
------------------------ ----------------------
Notes
FastForward innovations is an AIM quoted investment company
focused primarily on disruptive high growth life sciences and
technology businesses particularly within the medical cannabis
arena. The Company's strategy is to identify early stage
opportunities that have an upcoming investment catalyst and grow
its portfolio in terms of value whilst limiting the number of
investee companies to a level where relevant time can be devoted to
each.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSDFFEFESSEFD
(END) Dow Jones Newswires
March 31, 2020 08:15 ET (12:15 GMT)
Seed Innovations (LSE:SEED)
Historical Stock Chart
From Apr 2024 to May 2024
Seed Innovations (LSE:SEED)
Historical Stock Chart
From May 2023 to May 2024